(Yicai Global) April 14 -- CanSino Biologics moved to reassure investors that no serious blood clotting has been reported so far in recipients of its Covid-19 jab after shares of the Chinese vaccine maker sank.

“No blood clot-related serious adverse events have been reported in around 1 million vaccinations of Ad5-nCoV,” as its adenovirus vector shot for Covid-19 is called, the Tianjin-based company said in a filing today.

CanSino’s shares plunged in the wake of reports of some cases of a very rare and severe type of thrombosis in people who have had similar Covid-19 inoculations developed by Oxford University-AstraZeneca and Johnson & Johnson. Some countries have paused or age-restricted use of those companies’ adenovirus vector vaccines for Covid-19 because of blood-clotting.

CanSino’s shares [SHA:688185] ended today 6.3 percent lower in Shanghai at CNY361.99 (USD55.40) each, after earlier slumping as much as 13.7 percent. In Hong Kong, its stock [HKG:6185] lost up to 18.4 percent before closing down 7.5 percent at HKG289.20 (USD37.20). 

Editor: Tom Litting